- Poster presentation
- Open Access
A cost-effectiveness analysis of Maraviroc in treatment-experienced HIV patients in Scotland
© Lekander et al; licensee BioMed Central Ltd. 2008
- Published: 10 November 2008
- Incremental Cost
- Drug Experience
- Cohort Model
- Incremental Gain
The objective of this study was to perform a cost-effectiveness analysis of maraviroc therapy in patients with triple-class drug experience and/or triple-class drug resistance in Scotland, based on data from the MOTIVATE trials.
A Markov cohort model was developed in Excel based on the previously published ARAMIS model . Lifetime Maraviroc (MVC) treatment plus Optimized Background Therapy (OBT) was compared to standard OBT treatment in patients infected with CCR5-monotropic HIV-1. Disease states were defined according to CD4 cell counts and transition probabilities and drop-out rates were based on the MOTIVATE trials, complemented with data from the published literature. The model was populated with UK-specific costs (scaled to 2007 levels) and mortality rates for the Scottish general population. Efficacy was measured in quality-adjusted life-years (QALYs) and the analysis was performed from the perspective of the NHS. The base case input values and assumptions reflect a recent reimbursement submission.
MVC was associated with an incremental gain of 1.9 QALYs and incremental costs of £29,503 compared to standard OBT treatment, resulting in an incremental cost-effectiveness ratio (ICER) of £15,401 per QALY. Sensitivity analyses of input parameters and model assumptions produced ICERs in the range of £10,000–30,000.
The results indicated that it is potentially cost-effective to treat patients with MVC compared to standard OBT treatment in highly treatment-experienced HIV patients in Scotland.
- Chancellor J, et al: A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals. ISPOR 13th Annual International Meeting. Toronto, Canada, 3–7. 2008, May : Presentation IN3Google Scholar
This article is published under license to BioMed Central Ltd.